
Gaston De Serres

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3157851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses. PLoS ONE, 2014, 9, e92153.	2.5	347
2	Morbidity of Pertussis in Adolescents and Adults. Journal of Infectious Diseases, 2000, 182, 174-179.	4.0	298
3	The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Eurosurveillance, 2013, 18, .	7.0	192
4	Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine, 2015, 33, 2684-2689.	3.8	101
5	Largest Measles Epidemic in North America in a Decade—Quebec, Canada, 2011: Contribution of Susceptibility, Serendipity, and Superspreading Events. Journal of Infectious Diseases, 2013, 207, 990-998.	4.0	93
6	Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. Clinical Infectious Diseases, 2022, 75, 1980-1992.	5.8	92
7	Risk of Guillain-Barré Syndrome Following H1N1 Influenza Vaccination in Quebec. JAMA - Journal of the American Medical Association, 2012, 308, 175-81.	7.4	74
8	Higher Risk of Measles When the First Dose of a 2-Dose Schedule of Measles Vaccine Is Given at 12–14 Months Versus 15 Months of Age. Clinical Infectious Diseases, 2012, 55, 394-402.	5.8	72
9	Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement. PLoS ONE, 2017, 12, e0163586.	2.5	49
10	Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine, 2019, 37, 4243-4245.	3.8	47
11	Other Respiratory Viruses Are Important Contributors to Adult Respiratory Hospitalizations and Mortality Even During Peak Weeks of the Influenza Season. Open Forum Infectious Diseases, 2014, 1, ofu086.	0.9	45
12	Measles vaccine efficacy during an outbreak in a highly vaccinated population: Incremental increase in protection with age at vaccination up to 18 months. Epidemiology and Infection, 1995, 115, 315-323.	2.1	39
13	Measles in Children Vaccinated With 2 Doses of MMR. Pediatrics, 2013, 132, e1126-e1133.	2.1	31
14	Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine, 2013, 31, 5989-5996.	3.8	29
15	Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, Canada. Clinical Infectious Diseases, 2022, 75, e805-e813.	5.8	26
16	Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected. Clinical Infectious Diseases, 2003, 37, 1059-1066.	5.8	24
17	Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose. Clinical Infectious Diseases, 2017, 65, 1094-1102.	5.8	24
18	Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine – A randomized clinical trial. Vaccine, 2018, 36, 7017-7024.	3.8	24

GASTON DE SERRES

#	Article	IF	CITATIONS
19	Chemosensory Dysfunctions Induced by COVID-19 Can Persist up to 7 Months: A Study of Over 700 Healthcare Workers. Chemical Senses, 2021, 46, .	2.0	24
20	Recurrence Risk of Oculorespiratory Syndrome After Influenza Vaccination. Archives of Internal Medicine, 2004, 164, 2266.	3.8	23
21	Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013. Eurosurveillance, 2013, 18, .	7.0	23
22	Protection after Two Doses of Measles Vaccine Is Independent of Interval between Doses. Journal of Infectious Diseases, 1999, 180, 187-190.	4.0	21
23	Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine, 2018, 36, 8039-8046.	3.8	21
24	Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review. Pediatrics, 2017, 140, e20163707.	2.1	20
25	Randomized Controlled Ferret Study to Assess the Direct Impact of 2008–09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk. PLoS ONE, 2014, 9, e86555.	2.5	19
26	Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine. Expert Review of Vaccines, 2018, 17, 99-102.	4.4	18
27	Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE. Journal of Allergy and Clinical Immunology, 2012, 130, 1423-1426.	2.9	17
28	Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000–2001 season. Vaccine, 2002, 20, 2713-2719.	3.8	16
29	Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open, 2019, 9, e026953.	1.9	16
30	Measles in Canada Between 2002 and 2013. Open Forum Infectious Diseases, 2015, 2, ofv048.	0.9	15
31	Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis. Pediatrics, 2014, 134, e983-e991.	2.1	14
32	Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 718-727.e1.	3.8	14
33	Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis. BMC Infectious Diseases, 2020, 20, 251.	2.9	14
34	Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal. Vaccine, 2019, 37, 4996-5002.	3.8	12
35	Exposure to <i>Toxoplasma gondii</i> Through Consumption of Raw or Undercooked Meat: A Systematic Review and Meta-Analysis. Vector-Borne and Zoonotic Diseases, 2021, 21, 40-49.	1.5	12
36	Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent. Vaccine, 2020, 38, 715-718.	3.8	10

#	Article	IF	CITATIONS
37	Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. Infection Control and Hospital Epidemiology, 2022, 43, 102-104.	1.8	10
38	Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors. Vaccine, 2015, 33, 4464-4471.	3.8	9
39	Characterization and evolution of infection control practices among severe acute respiratory coronavirus virus 2 (SARS-CoV-2)–infected healthcare workers in acute-care hospitals and long-term care facilities in QuA©bec, Canada, Spring 2020. Infection Control and Hospital Epidemiology, 2022, 43, 481-489.	1.8	9
40	Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine, 2016, 34, 2053-2054.	3.8	8
41	Rate of Recurrence of Adverse Events Following Immunization. Pediatric Infectious Disease Journal, 2019, 38, 377-383.	2.0	8
42	Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18â€ ⁻ months of age. Vaccine, 2018, 36, 6688-66	94 <mark>.^{3.8}</mark>	7
43	Post-immunisation fever and the antibody response to measles-containing vaccines. Epidemiology and Infection, 2018, 146, 1584-1592.	2.1	7
44	Persisting chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month follow-up. Chemical Senses, 2022, 47, .	2.0	6
45	Assessment of naturally acquired neutralizing antibodies against rabies Lyssavirus in a subset of Nunavik's Inuit population considered most at risk of being exposed to rabid animals. Zoonoses and Public Health, 2019, 66, 533-539.	2.2	5
46	Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13–2016/17, the Canadian Vaccine Safety Network. Vaccine, 2020, 38, 3582-3590.	3.8	5
47	Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness. Vaccine, 2014, 32, 6596.	3.8	4
48	Canadian vaccine research networks: Vaccine safety resources for Canada. Canada Communicable Disease Report, 2015, 41, 18-23.	1.3	4
49	Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region. BMC Infectious Diseases, 2015, 15, 227.	2.9	3
50	Children vaccination coverage surveys: Impact of multiple sources of information and multiple contact attempts. Vaccine, 2020, 38, 1202-1210.	3.8	3
51	Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network. Paediatrics and Child Health, 2014, 19, 310-4.	0.6	3
52	Safety of revaccination of patients affected by the oculo-respiratory syndrome (ORS) following influenza vaccination. Canada Communicable Disease Report, 2004, 30, 9-16.	1.3	3
53	Persistence of infectivity in elderly individuals diagnosed with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection 10 days after onset of symptoms: A cross-sectional study. Infection Control and Hospital Epidemiology, 2023, 44, 659-662.	1.8	3
54	Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity. PLoS ONE, 2017, 12, e0186070.	2.5	1

#	Article	IF	CITATIONS
55	Impact of the addition of new vaccines in the early childhood schedule on vaccine coverage by 24†months of age from 2006 to 2016 in Quebec, Canada. Vaccine, 2018, 36, 4383-4391.	3.8	1
56	A mixed vaccination schedule of HPV vaccine induces a 100% seropositivity to all 9 HPV types included in 9vHPV vaccine. Vaccine, 2019, 37, 4422-4423.	3.8	1
57	Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network. Allergy, Asthma and Clinical Immunology, 2022, 18, 32.	2.0	0